The use of unrelated umbilical cord blood (UCB) has grown as an allogeneic source of hematopoietic cells for transplantation of patients with hematologic malignancies. As the number of UCB transplantation procedures has grown, an increasing number of publications have focused on disease-specific outcomes.
Methods
This review focuses on the outcome data following UCB transplantation in subsets of hematologic malignancies in which experience with this graft source is greater.
Results
Registry and single-institution reports regarding the outcomes of children and adults with acute leukemias after UCB transplantation include many patients, while data on the clinical outcomes of other leukemias are limited due in part to the small number of patients with these diseases. UCB is now routinely used as a source of hematopoietic stem cells (HSCs) in pediatric allogeneic transplantation when a suitable sibling donor is not available. Data also support the use of UCB as an alternative source of HSC for transplantation of patients with hematologic malignancies who lack a more conventional donor. Current data also support UCB for patients who require an allograft in the setting of prospective clinical trials.
Conclusions
Along with safety and feasibility in UCB transplantation, continued study is needed that focuses on issues such as accelerating engraftment, extending access, ensuring quality, and examining outcomes in specific subgroups of patients.
References
1.
WagnerJ.E., KernanN.A., SteinbuchM.. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and nonmalignant disease.Lancet.1995; 346(8969): 214–219.
2.
WagnerJ.E., RosenthalJ., SweetmanR.. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versushost disease.Blood.1996; 88(3): 795–802.
3.
KurtzbergJ., GrahamM., CaseyJ.. The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation.Blood Cells.1994; 20(2-3): 275–283; discussion 284.
4.
GluckmanE., RochaV., Boyer-ChammardA.. Outcome of cordblood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group.N Engl J Med.1997; 337(6): 373–381.
5.
RubinsteinP., CarrierC., ScaradavouA.. Outcomes among 562 recipients of placental-blood transplants from unrelated donors.N Engl J Med.1998; 339(22): 1565–1577.
6.
LaughlinM.J., BarkerJ., BambachB.. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.N Engl J Med.2001; 344(24): 1815–1822.
7.
WagnerJ.E., BarkerJ.N., De ForT.E.. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.Blood.2002; 100(5): 1611–1618.
8.
OhnumaK., IsoyamaK., IkutaK.. Cord blood transplantation from HLA-mismatched unrelated donors as a treatment for children with haematological malignancies.Br J Haematol.2001; 112(4): 981–987.
9.
IsoyamaK., OhnumaK., KatoK.. Cord blood transplantation from unrelated donors: a preliminary report from the Japanese Cord Blood Bank Network.Leuk Lymphoma.2003; 44(3): 429–438.
10.
LocatelliF., RochaV., ChastangC.. Factors associated with outcome after cord blood transplantation in children with acute leukemia.Blood.1999; 93(11): 3662–3671.
11.
BarkerJ.N., DaviesS.M., De ForT.. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis.Blood.2001; 97(10): 2957–2961.
12.
RochaV., CornishJ., SieversE.L.. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.Blood.2001; 97(10): 2962–2971.
13.
MichelG., RochaV., ChevretS.. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis.Blood.2003; 102(13): 4290–4297.
14.
JacobsohnD.A., HewlettB., RanalliM.. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.Bone Marrow Transplant.2004; 34(10): 901–907.
15.
GluckmanE., RochaV., ArceseW.. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.Exp Hematol.2004; 32(4): 397–407.
16.
WallD.A., CarterS.L., KernanN.A.. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.Biol Blood Marrow Transplant.2005; 11(8): 637–646.
17.
EapenM., RubinsteinP., ZhangM.J.. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.Lancet.2007; 369(9577): 1947–1954.
18.
KurtzbergJ., PrasadV.K., CarterS.L.. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.Blood.2008; 112(10): 4318–4327.
19.
CornettaK., LaughlinM., CarterS.. Umbilical cord blood transplantation in adults: Results of the prospective cord blood transplantation (COBLT).Biol Blood Marrow Transplant.2005; 11(2): 149–160.
20.
LaughlinM.J., EapenM., RubinsteinP.. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.N Engl J Med.2004; 351(22): 2265–2275.
21.
RochaV., LabopinM., SanzG.. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.N Engl J Med.2004; 351(22): 2276–2285.
22.
TakahashiS., IsekiT., OoiJ.. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.Blood.2004; 104(12): 3813–3820.
23.
TakahashiS., OoiJ., TomonariA.. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stemcell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen.Blood.2007; 109(3): 1322–1330.
24.
KumarP., De ForT.E., BrunsteinC.. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.Biol Blood Marrow Transplant.2008; 14(12): 1394–1400.
25.
TomblynM.B., AroraM., BakerK.S.. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.J Clin Oncol.2009; 27(22): 3634–3641.
26.
AtsutaY., SuzukiR., Nagamura-InoueT.. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.Blood.2009; 113(8): 1631–1638.
27.
EapenM., RochaV., SanzG.. Effect of graft source on unrelated donor haemopoietic stemcell transplantation in adults with acute leukaemia: a retrospective analysis.Lancet Oncol.2010; 11(7): 653–660.
28.
BrunsteinC.G., GutmanJ.A., WeisdorfD.J.. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood.Blood.2010; 116(22): 4693–4699.
29.
OoiJ., IsekiT., TakahashiS.. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia.Blood.2004; 103(2): 489–491.
30.
SanzJ., SanzM.A., SaavedraS.. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.Biol Blood Marrow Transplant.2010; 16(1): 86–94.
31.
BrunsteinC.G., SetubalD., TomblynM.. Umbilical cord blood transplant after reduced intensity conditioning provides outcomes comparable HLA-matched siblings for patients with high risk and advanced acute myeloid leukemia.Blood.2006; 108(11): 606. Abstract.
BrunsteinC.G., BarkerJ.N., WeisdorfD.J.. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.Blood.2007; 110(8): 3064–3070.
34.
DrukerB.J., SawyersC.L., KantarjianH.. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med.2001; 344(14): 1038–1042.
35.
DrukerB.J., TalpazM., RestaD.J.. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med.2001; 344(14): 1031–1037.
36.
KantarjianH., ShahN.P., HochhausA.. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med.362(24): 2260–2270.
37.
SaglioG., KimD.W., IssaragrisilS.. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.N Engl J Med.2010; 362(24): 2251–2259.
38.
McGlaveP.B., ShuX.O., WenW.. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years’ experience of the national marrow donor program.Blood.2000; 95(7): 2219–2225.
39.
ChioreanE.G., De ForT.E., WeisdorfD.J.. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant.2004; 10(3): 171–177.
40.
DazziF., SzydloR.M., CraddockC.. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.Blood.2000; 95(1): 67–71.
41.
GuglielmiC., ArceseW., DazziF.. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.Blood.2002; 100(2): 397–405.
42.
MaschanA.A., SkorobogatovaE.V., SamotchatovaE.V.. A successful cord blood transplant in a child with second accelerated phase chronic myeloid leukemia following lymphoid blast crisis.Bone Marrow Transplant.2000; 25(2): 213–215.
43.
PecoraA.L., StiffP., JennisA.. Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood.Bone Marrow Transplant.2000; 25(7): 797–799.
44.
ArceseW., RochaV., LabopinM.. Unrelated cord blood transplants in adults with hematologic malignancies.Haematologica.2006; 91(2): 223–230.
45.
BrunsteinC.B., SetubalD., De ForT.. Umbilical cord blood transplantation for adult patients with chronic myeloid leukemia.Biol Blood Marrow Transplant.2007; 13(2 suppl): 84.
46.
SanzG.F., SaavedraS., JiménezC.. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution.Bone Marrow Transplant.2001; 27(7): 693–701.
47.
SanzJ., MontesinosP., SaavedraS.. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.Biol Blood Marrow Transplant.2010; 16(11): 1589–1595.
48.
OoiJ., IsekiT., TakahashiS.. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome.Blood.2003; 101(12): 4711–4713.
49.
SatoA., OoiJ., TakahashiS.. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes.Bone Marrow Transplant.2011; 46(2): 257–261.
50.
WarlickE.D., CiocA., De ForT.. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.Biol Blood Marrow Transplant.2009; 15(1): 30–38.
51.
AndoT., YujiriT., TominagaT.. Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity.Eur J Haematol.2005; 74(2): 175–179.
52.
KasaharaI., NishioM., YamamotoS.. Cord blood transplantation with a reducedintensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib.Int J Hematol.2009; 90(3): 413–415.
ToubaiT., HirateD., ShonoY.. Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma.Int J Lab Hematol.2008; 30(1): 75–81.
55.
YamadaT., TomonariA., TakahashiS.. Unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous transplantation for multiple myeloma.Int J Hematol.2004; 80(4): 377–380.
56.
YujiK., MiyakoshiS., KatoD.. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma.Biol Blood Marrow Transplant.2005; 11(4): 314–318.
57.
MajhailN.S., WeisdorfD.J., WagnerJ.E.. Comparable results of umbilical cord blood and HL-A-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.Blood.2006; 107(9): 3804–3807.
58.
WakeA., UchidaN., IshiwataK.. Single institute analysis of reduced intensity cord blood transplantation from unrelated donors for adults with advanced lymphoid malignancies.Blood (ASH Annual Meeting Abstracts).2008; 112: 1963. Abstract.
59.
BrunsteinC.G., CanteroS., CaoQ.. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.Biol Blood Marrow Transplant.2009; 15(2): 214–222.
60.
RodriguesC.A., SanzG., BrunsteinC.G.. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.J Clin Oncol.2009; 27(2): 256–263.
61.
RodriguesC.A., CanalsC., BrunsteinC.. Comparison of outcomes after unrelated cord blood transplantation and matched unrelated donor RIC transplantation for lymphoid malignancies: a Eurocord-Netcord Group/Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.Blood (ASH Annual Meeting Abstracts).2009; 114: 663.
62.
FernändezM.N., RegidorC., CabreraR.. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor.Exp Hematol.2003; 31(6): 535–544.
63.
DelaneyC., HeimfeldS., Brashem-SteinC.. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.Nat Med.2010; 16(2): 232–236.
64.
RatajczakM.Z., RecaR., WysoczynskiM.. Modulation of the SDF-1-CXCR4 axis by the third complement component (C3)–implications for trafficking of CXCR4+ stem cells.Exp Hematol.2006; 34(8): 986–995.
65.
BrunsteinC.G., BarkerJ.N., WeisdorfD.J.. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units.Bone Marrow Transplant.2009; 43(12): 935–940.
66.
FrassoniF., GualandiF., PodestàM.. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.Lancet Oncol.2008; 9(9): 831–839.
67.
BrunsteinC.G., MillerJ.S., CaoQ.. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.Blood.2011; 117(3): 1061–1070.
68.
BrunsteinC.G., WagnerJ.E., WeisdorfD.J.. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.Blood.2009; 113(22): 5628–5634.
69.
WillemzeR., RodriguesC.A., LabopinM.. KIR-ligand incompatibility in the graft-versushost direction improves outcomes after umbilical cord blood transplantation for acute leukemia.Leukemia.2009; 23(3): 492–500.
